|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ERF |
Gene summary for ERF |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ERF | Gene ID | 2077 |
| Gene name | ETS2 repressor factor | |
| Gene Alias | CHYTS | |
| Cytomap | 19q13.2 | |
| Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | P50548 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 2077 | ERF | S43 | Human | Liver | Cirrhotic | 2.30e-06 | -2.22e-01 | -0.0187 |
| 2077 | ERF | HCC1_Meng | Human | Liver | HCC | 3.60e-53 | -5.39e-02 | 0.0246 |
| 2077 | ERF | HCC2_Meng | Human | Liver | HCC | 3.91e-11 | -8.56e-02 | 0.0107 |
| 2077 | ERF | cirrhotic1 | Human | Liver | Cirrhotic | 7.07e-06 | 1.07e-01 | 0.0202 |
| 2077 | ERF | cirrhotic2 | Human | Liver | Cirrhotic | 6.28e-04 | 3.11e-02 | 0.0201 |
| 2077 | ERF | Pt13.b | Human | Liver | HCC | 7.22e-05 | -1.65e-02 | 0.0251 |
| 2077 | ERF | S014 | Human | Liver | HCC | 3.88e-15 | 7.21e-01 | 0.2254 |
| 2077 | ERF | S015 | Human | Liver | HCC | 1.11e-15 | 8.51e-01 | 0.2375 |
| 2077 | ERF | S016 | Human | Liver | HCC | 9.70e-12 | 5.70e-01 | 0.2243 |
| 2077 | ERF | S028 | Human | Liver | HCC | 1.06e-04 | 3.79e-01 | 0.2503 |
| 2077 | ERF | C04 | Human | Oral cavity | OSCC | 1.93e-08 | 8.16e-01 | 0.2633 |
| 2077 | ERF | C21 | Human | Oral cavity | OSCC | 8.56e-06 | 3.56e-01 | 0.2678 |
| 2077 | ERF | C30 | Human | Oral cavity | OSCC | 1.09e-32 | 1.48e+00 | 0.3055 |
| 2077 | ERF | C38 | Human | Oral cavity | OSCC | 5.00e-06 | 1.14e+00 | 0.172 |
| 2077 | ERF | C43 | Human | Oral cavity | OSCC | 3.70e-18 | 4.47e-01 | 0.1704 |
| 2077 | ERF | C51 | Human | Oral cavity | OSCC | 5.34e-04 | 4.64e-01 | 0.2674 |
| 2077 | ERF | C06 | Human | Oral cavity | OSCC | 2.38e-04 | 1.28e+00 | 0.2699 |
| 2077 | ERF | C08 | Human | Oral cavity | OSCC | 3.61e-25 | 6.17e-01 | 0.1919 |
| 2077 | ERF | C09 | Human | Oral cavity | OSCC | 2.70e-24 | 1.18e+00 | 0.1431 |
| 2077 | ERF | LN46 | Human | Oral cavity | OSCC | 9.67e-06 | 6.54e-01 | 0.1666 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00316479 | Breast | Precancer | regulation of protein stability | 38/1080 | 298/18723 | 3.73e-06 | 1.19e-04 | 38 |
| GO:003164714 | Breast | IDC | regulation of protein stability | 50/1434 | 298/18723 | 1.14e-07 | 6.57e-06 | 50 |
| GO:003164724 | Breast | DCIS | regulation of protein stability | 51/1390 | 298/18723 | 1.63e-08 | 1.15e-06 | 51 |
| GO:004854510 | Cervix | CC | response to steroid hormone | 74/2311 | 339/18723 | 5.71e-07 | 2.09e-05 | 74 |
| GO:00305229 | Cervix | CC | intracellular receptor signaling pathway | 60/2311 | 265/18723 | 1.89e-06 | 5.97e-05 | 60 |
| GO:003164710 | Cervix | CC | regulation of protein stability | 63/2311 | 298/18723 | 1.14e-05 | 2.45e-04 | 63 |
| GO:190165410 | Cervix | CC | response to ketone | 45/2311 | 194/18723 | 1.83e-05 | 3.44e-04 | 45 |
| GO:00165705 | Cervix | CC | histone modification | 84/2311 | 463/18723 | 1.70e-04 | 2.01e-03 | 84 |
| GO:00325704 | Cervix | CC | response to progesterone | 13/2311 | 37/18723 | 2.99e-04 | 3.21e-03 | 13 |
| GO:00713839 | Cervix | CC | cellular response to steroid hormone stimulus | 40/2311 | 204/18723 | 1.93e-03 | 1.42e-02 | 40 |
| GO:00305188 | Cervix | CC | intracellular steroid hormone receptor signaling pathway | 25/2311 | 116/18723 | 3.59e-03 | 2.30e-02 | 25 |
| GO:0031647 | Colorectum | AD | regulation of protein stability | 108/3918 | 298/18723 | 6.33e-10 | 5.08e-08 | 108 |
| GO:0010639 | Colorectum | AD | negative regulation of organelle organization | 114/3918 | 348/18723 | 1.41e-07 | 6.49e-06 | 114 |
| GO:0051052 | Colorectum | AD | regulation of DNA metabolic process | 116/3918 | 359/18723 | 2.47e-07 | 1.00e-05 | 116 |
| GO:0051054 | Colorectum | AD | positive regulation of DNA metabolic process | 73/3918 | 201/18723 | 3.27e-07 | 1.29e-05 | 73 |
| GO:2001252 | Colorectum | AD | positive regulation of chromosome organization | 35/3918 | 82/18723 | 6.90e-06 | 1.72e-04 | 35 |
| GO:2000278 | Colorectum | AD | regulation of DNA biosynthetic process | 41/3918 | 106/18723 | 2.17e-05 | 4.33e-04 | 41 |
| GO:0001701 | Colorectum | AD | in utero embryonic development | 110/3918 | 367/18723 | 2.36e-05 | 4.62e-04 | 110 |
| GO:2001020 | Colorectum | AD | regulation of response to DNA damage stimulus | 71/3918 | 219/18723 | 4.38e-05 | 7.65e-04 | 71 |
| GO:0032206 | Colorectum | AD | positive regulation of telomere maintenance | 23/3918 | 52/18723 | 1.31e-04 | 1.88e-03 | 23 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ERF | CD8TRM | Cervix | CC | TRIM24,LINC00641,EVA1B, etc. | 1.62e-01 |  |
| ERF | CD8TRM | Cervix | N_HPV | TRIM24,LINC00641,EVA1B, etc. | 2.98e-01 |  |
| ERF | QUIE | Esophagus | ESCC | IER5,NUMBL,SERTAD1, etc. | 7.95e-02 |  |
| ERF | STM | Esophagus | HGIN | IER5,NUMBL,SERTAD1, etc. | 2.50e-01 |  |
| ERF | STM | Liver | Healthy | PMAIP1,FOXA2,RQCD1, etc. | 6.73e-01 |  |
| ERF | MSC.MVA | Liver | Cirrhotic | CTU1,ZNF781,ABCF2, etc. | 1.27e-01 |  |
| ERF | MVA | Liver | Healthy | CTU1,ZNF781,ABCF2, etc. | 5.47e-02 | |
| ERF | MSC.MVA | Liver | Healthy | CTU1,ZNF781,ABCF2, etc. | 2.64e-02 | |
| ERF | TFH | Lung | IAC | IL15RA,AC007952.4,FRYL, etc. | 1.69e-01 |  |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ERF | SNV | Missense_Mutation | novel | c.260N>G | p.Tyr87Cys | p.Y87C | P50548 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-4H-AAAK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | CR |
| ERF | SNV | Missense_Mutation | c.1541N>A | p.Arg514His | p.R514H | P50548 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.511) | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ERF | SNV | Missense_Mutation | rs368169058 | c.427N>T | p.Arg143Cys | p.R143C | P50548 | protein_coding | deleterious(0) | probably_damaging(0.928) | TCGA-W8-A86G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| ERF | SNV | Missense_Mutation | c.610N>A | p.Pro204Thr | p.P204T | P50548 | protein_coding | tolerated(0.53) | benign(0.362) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR | |
| ERF | SNV | Missense_Mutation | c.1471N>A | p.Asp491Asn | p.D491N | P50548 | protein_coding | deleterious(0) | possibly_damaging(0.746) | TCGA-EK-A2PG-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ERF | SNV | Missense_Mutation | c.1513N>C | p.Glu505Gln | p.E505Q | P50548 | protein_coding | tolerated_low_confidence(0.79) | benign(0.014) | TCGA-EK-A2RB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| ERF | SNV | Missense_Mutation | novel | c.1519G>A | p.Glu507Lys | p.E507K | P50548 | protein_coding | deleterious_low_confidence(0) | benign(0.007) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ERF | SNV | Missense_Mutation | c.1628N>C | p.Leu543Pro | p.L543P | P50548 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.996) | TCGA-A6-3809-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ERF | SNV | Missense_Mutation | rs767080643 | c.616N>A | p.Ala206Thr | p.A206T | P50548 | protein_coding | tolerated(0.43) | benign(0.082) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ERF | SNV | Missense_Mutation | novel | c.502N>C | p.Ser168Pro | p.S168P | P50548 | protein_coding | tolerated(0.09) | possibly_damaging(0.763) | TCGA-AA-3877-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |